Cannabis as Medicine

Cannabis and Mental Health: A Review

PMID: 41801216 . DOI: 10.1001/jamainternmed.2025.8215 Abstract Importance: Cannabis use is common among those with mental health conditions, and many people report using cannabis to manage mental health symptoms. It is important for clinicians to understand the lack of clear benefits of cannabis for mental health conditions and the potential for substantial adverse effects. Observations: Overall, the potential benefits of […]

Cannabis and Mental Health: A Review Read More »

Association of cannabis use and lung cancer: a retrospective cohort study

Received April 16, 2026; Published online April 22, 2026 DOI: 10.1016/j.lungcan.2026.109421 External Link   Highlights Individuals with cannabis use disorder had an increased risk of any lung and/or bronchus cancer in this cohort study. Increased risk for small cell carcinoma, squamous cell carcinoma, and adenocarcinoma was observed. Further studies are required to explore the strength of this

Association of cannabis use and lung cancer: a retrospective cohort study Read More »

Policy brief: Prenatal Cannabis Exposure and Foetal Neurodevelopment

Overview Recent human evidence adds weight to longstanding concerns that cannabis use during pregnancy can interfere with foetal brain development in biologically meaningful ways. The 2026 study by Ugartemendia and colleagues links prenatal cannabis exposure with altered cannabinoid signalling, altered dopamine-related signalling, and shifts in regulatory microRNAs in the developing human brain, with stronger effects

Policy brief: Prenatal Cannabis Exposure and Foetal Neurodevelopment Read More »

What the FDA Knows About CBD and Cancer: Regulatory Evidence, Expert Commentary, and Public Health Failure

 Background. Cannabidiol (CBD) now dominates consumer health markets worldwide. Manufacturers market it predominantly on the basis of perceived safety. However, CBD carcinogenicity FDA evidence, generated during the pharmaceutical approval process for purified CBD (Epidiolex, GW Research Ltd, NDA 210365), raises substantive concerns that regulators have not communicated to the public, prescribers, or policymakers. Evidence reviewed. This

What the FDA Knows About CBD and Cancer: Regulatory Evidence, Expert Commentary, and Public Health Failure Read More »

Cannabinoid impacts on ethnic modulation of atrial septal defect prevalence USA

Professors Albert Stuart Reece , Gary Kenneth Hulse  Abstract Objective: To conduct a detailed epidemiological exploration of the relative contributions of cannabis and ethnicity to US atrial septal defect (ASD) rates (ASDR). Study design: State-based ASDR data from the US National Births Defects Prevention Network, substance use, income and ethnicity data analysed in RStudio. Results: Ethnic effects were significant with

Cannabinoid impacts on ethnic modulation of atrial septal defect prevalence USA Read More »

Compassion as Cover: The Six-Year Unravelling of New Zealand’s Medicinal Cannabis Scheme

In 2020, New Zealand held the world’s first national referendum on recreational cannabis legalisation. Fifty-one percent voted against it. The public considered the question directly and said no. That same year, the New Zealand Medicinal’s Cannabis Scheme came into effect. Its architects described it as “a bill about cultivation, cannabidiol and compassion.” It would provide

Compassion as Cover: The Six-Year Unravelling of New Zealand’s Medicinal Cannabis Scheme Read More »

Combining Cannabis and Opioids Does Not Relieve Knee Arthritis Pain, Major Trial Finds

Millions of people with chronic knee pain have hoped that cannabis and opioids for pain might work better together. A new clinical trial published in Anesthesiology has challenged that idea. The research found no meaningful benefit from combining the two drugs. In some cases, the combination made things worse. What the Study Found About Cannabis and Opioids

Combining Cannabis and Opioids Does Not Relieve Knee Arthritis Pain, Major Trial Finds Read More »

Scroll to Top